Catalyst ligands

68737-65-5, (1R,2R)-N,N’-Dimethyl-1,2-cyclohexanediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 56 Preparation of N-(4-methylphenyl)benzamide using 4-chlorotoluene and N,N’-dimethyl-trans-1,2-cyclohexanediamine at 110 C. An oven-dried resealable Schlenk tube was charged with CuI (20 mg, 0.105 mmol, 5.1 mol %), benzamide (250 mg, 2.06 mmol), K2CO3 (600 mg, 4.34 mmol), evacuated and backfilled with argon. N,N’-Dimethyl-trans-1,2-cyclohexanediamine (35 muL, 0.222 mmol, 11 mol %) and 4-chlorotoluene (1.0 mL, 8.44 mmol) were added under argon. The Schlenk tube was sealed and the reaction mixture was stirred magnetically at 110 C. for 23 h. The resulting dark blue-green suspension was cooled to room temperature and filtered through a 0.5*1 cm pad of silica gel eluding with 10 mL of ethyl acetate. The light brown filtrate was concentrated and the residue was purified by flash chromatography on silica gel (2*20 cm; hexane-ethyl acetate 2:1; 15 mL fractions). Fractions 4-10 were concentrated, the solid residue was suspended in 10 mL of hexane and filtered to provide 392 mg (90% yield) of the product as fine white needles.

68737-65-5, 68737-65-5 (1R,2R)-N,N’-Dimethyl-1,2-cyclohexanediamine 2733821, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Buchwald, Stephen L.; Klapars, Artis; Antilla, Jon C.; Job, Gabriel E.; Wolter, Martina; Kwong, Fuk Y.; Nordmann, Gero; Hennessy, Edward J.; US2003/65187; (2003); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,62937-45-5

C) (2R)-1-((1-(4-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl)piperidin-4-yl)carbonyl)pyrrolidine-2-carbonitrile (crude crystals) To a suspension of 1-(4-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl)piperidine-4-carboxylic acid (80 g) and acetonitrile (0.32 L) were added DIPEA (0.21 L), (R)-prolinamide (40 g) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (1.7M ethyl acetate solution, 0.28 L) at 0C. The mixture was stirred at room temperature for 1 hr, to the mixture was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (1.7M ethyl acetate solution, 0.35 L), and the mixture was stirred overnight at 70C. To the mixture was added saturated aqueous sodium hydrogen carbonate solution (1600 mL) at 0C, and the mixture was extracted with a mixed solvent of ethyl acetate and THF. The organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solution was purified by silica gel column chromatography (ethyl acetate). The solvent was evaporated under reduced pressure, to the residue was added diisopropyl ether, and the mixture was stirred overnight at room temperature. The solid was collected by filtration, and washed with diisopropyl ether to give the title compound (93 g). 1H NMR (300 MHz, DMSO-d6) 5 1.57-1.82 (4H, m), 1.89-2.30 (7H, m), 2.53-2.83 (3H, m), 2.86-3.06 (2H, m), 3.41-3.58 (1H, m), 3.62-3.75 (1H, m), 4.72 (1H, dd, J = 7.4, 4.0 Hz), 7.53 (1H, d, J = 5.3 Hz), 7.63 (1H, s), 8.31 (1H, d, J = 5.3 Hz), 8.41 (1H, s), 8.43 (1H, s).

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Takeda Pharmaceutical Company Limited; KOIKE, Tatsuki; KAJITA, Yuichi; YOSHIKAWA, Masato; IKEDA, Shuhei; KIMURA, Eiji; HASUI, Tomoaki; NISHI, Toshiya; FUKUDA, Hiromi; EP2933247; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33454-82-9,Lithium trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

General procedure: To the solution of 2-Cl (186 mg, 0.25 mmol) dissolvedin5.0 mL of methanol/CH2Cl2 (1/9), a 5% aqueous solution of sodiumtetrafluoroborate (1.5 g, 0.41 mmol) was added. The solution was stirredat room temperature for 1 h. Reaction was monitored by Alumina(Al2O3) TLC plate in MeOH/CH2Cl2 (5/95); an Rf ~ 0.9 of product washigher than Rf ~ 0.5 of 2-Cl. The organic layer was passed through ashort Al2O3 flash column. The crude product was collected after solventswere removed. The product isolated as fine off white powder was obtainedafter recrystallization from isopropanol/ethyl acetate. Yield 70%;, 33454-82-9

33454-82-9 Lithium trifluoromethanesulfonate 3664839, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Wang, Ren-Tzong; Jane Tsai, Suh-Jen; Lee, Gene-Hsiang; Lai, Chung K.; Dyes and Pigments; vol. 173; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

135616-40-9, (R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Beispiel 1 244,3 g (0.448 moi) (R, R)-2, 2 – [1, 2-CYCLOHEXANDIYL) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] (Illa) werden in 1500 ML Dichlormethan geloest und mit einer Loesung von 60,0 g (0,237 mol) Vanadylsulfat-Pentahydrat in 2000 ml Methanol versetzt. Die Reaktionsmischung ruehrt fuer 24 h bei Raumtemperatur. Anschliessend wird das Loesungsmittel abdestilliert, der Rueckstand in 1000 ml Dichlormethan aufgenommen und mit 1000 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der organischen Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 247,7 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (II) : (III) =68% : 13% : 19%. [A] D20 =-400 (c = 0,01, Chloroform). Beispiel 2 5,46 g (0.01 mol) (R, R)-2, 2 – [1, 2-CYCLOHEXANDIYL) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] (Illa) werden in 12,5 ml Dichlormethan geloest und mit einer Loesung von 1,26 g (0,005 mol) VANADYLSULFAT-PENTAHYDRAT in 12,5 ML Methanol versetzt. Die Reaktionsmischung ruehrt fuer eine Stunde bei 40 C. Anschliessend wird das Loesungsmittel abdestilliert, der Rueckstand in 50 ml Dichlormethan aufgenommen und mit 100 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der organischen Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 3,5 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (H) : (III) = 71 % : 10% : 19%.

135616-40-9, The synthetic route of 135616-40-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1671-87-0,3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine,as a common compound, the synthetic route is as follows.

A 5¡Á10-6 M solution of compound 4 in 1:1 ethanol:H20 and a 5¡Á10-6 M solution of compound 12 in ethanol were prepared separately. 1 mL of each solution was added to a 3-mL UV cuvette, and the absorbance was measured every five minutes at room temperature for 40 minutes. Tetrazine 4 has an absorption maximum at 292 nm, and the product 13 has an absorption maximum at 312 nm. Also, product 13 displays significant absorption at 340 nm (e=12000), whereas tetrazine 4 displays minimal absorption (e=3000) at 340 nm. With monitoring at 292, 312 and 340 nm, the reaction was considered to be completed in 40 min

1671-87-0, 1671-87-0 3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine 315109, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; University of Delaware; US2009/23916; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

7328-91-8, 2,2-Dimethylpropane-1,3-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Pyridine-2-carbaldehyde (30 mmol, 3.21 g)And 2,2-dimethyl-1,3-propanediamine (15 mmol, 1.53 g)30mL of methanol mixed,After 7.0 hours at room temperature,Slowly add NaBH4 (120 mmol, 4.54 g) slowly while stirring in an ice-water bath Slowly warmed to 70 for 5 hours.Stop the reaction,Cool to room temperature,Rotate the reaction solution.Then 50mL CH2Cl2 dissolved, filtered, Filtrate spin dry,Have yellow oily sticky substance.After dissolving the above yellow oily dope in 30 mL of methanol,To this was added an equimolar amount of aqueous formaldehyde solution,After stirring at room temperature for 3 hours,The solvent was removed under reduced pressure,Isolated and purified by column chromatography to give 3,3-dimethyl-1,3-bis (2-picolyl) hexahydropyrimidine (3.96 g, yield 89percent)., 7328-91-8

Big data shows that 7328-91-8 is playing an increasingly important role.

Reference£º
Patent; Henan University of Technology; Yang Liangru; Mai Wenpeng; Mao Pu; Xiao Yongmei; Yuan Jinwei; Qu Lingbo; (12 pag.)CN104744519; (2017); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

Step 4: Preparation of tetrabutylammonium salt of (2S,5R)-N-[(3/?)-l-(ferf-butoxycarbonyl) piperidine-3-carbonyl]-6-(sulfooxy)-7-oxo-l,6-diazabicyclo[3.2.1]octane-2-carboxamide: To a stirred solution of (2S,5 ?)-N-[(3^)-l-(ieri-butoxycarbonyl)piperidine-3-carbonyl]-6-hydroxy-7-oxo- l,6-diazabicyclo[3.2.1]octane-2-carboxamide (0.480 g, 0.0012mol) in dimethylformamide (4.8 ml), at about 10C, was added dimethylformamide sulphur trioxide complex (0.207 g, 0.0013mol) in one portion. The reaction mass was stirred at the same temperature for 30 minutes and allowed to warm to room temperature. After 1 hour of stirring, to the reaction mixture was added, slowly, a solution of tetrabutylammonium acetate (0.408 g, 0.0013 mol) in dichloro methane (2 ml) and the stirring continued further. After 1 hour, the solvent from the reaction mixture was evaporated under reduced pressure to obtain an oily residue. The oily mass was co-evaporated with xylene (2×10 ml) resulting in a thick mass. This mass was partitioned between dichloromethane (10 ml) and water (10 ml) for three times. The combined organic extracts were washed with water (3×10 ml), dried (over anhydrous sodium sulphate) and the solvent was evaporated under reduced pressure. The resulting oily mass was triturated with ether (3×10 ml), each time the ether layer was decanted and finally the residue was concentrated under reduced pressure to obtain 0.7 g of the titled product as white foam in 80% yield.Analysis:475.4 (M-l) as free acid; for Molecular Weight: 717.95 and Molecular Formula:

10534-59-5, The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; WOCKHARDT LIMITED; TADIPARTHI, Ravikumar; PATIL, Vijaykumar Jagdishwar; KALE, Amol; SHAIKH, Mohammad Usman; PATEL, Mahesh Vithalbhai; (65 pag.)WO2016/116788; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The synthetic route of binary and ternary europium complexes C1-C5 is demonstrated in Scheme 2. A solution of EFBA (3 mmol) in ethanol was added dropwise to the aqueous solution of europium nitrate (1 mmol) with constant stirring on magnetic stirrer at room temperature. pH of the resulting mixture was set between 6-7 by using dilute NaOH (0.05 M) and white color precipitates were obtained. The resulting precipitates were vaccum filtered along with washing of water and ethanol to remove the unreacted ligand and then dried in vaccum desiccator to obtain the white powder of Eu(EFBA)3(H2O)2 (C1) complex. Complexes C2-C5 were prepared by the same procedure as adopted for the synthesis of complex C1 but in addition to the reaction mixture of EFBA (3 mmol) and europium nitrate (1 mmol) there is extra addition of ethanolic solution of neo (1 mmol), batho (1 mmol), phen (1 mmol), and bipy (1 mmol) for the synthesis of ternary europium complexes C2-C5, respectively., 1662-01-7

1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Devi, Rekha; Bala, Manju; Khatkar, S. P.; Taxak, V. B.; Boora, Priti; Journal of Fluorine Chemistry; vol. 181; (2016); p. 36 – 44;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

7328-91-8, 2,2-Dimethylpropane-1,3-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

N1-(5-chloro-4-(1-(phenylsulfonyl)-1H-indol-3-yl)pyrimidin-2-yl)-2,2-dimethylpropane-1,3-diamineA suspension of 3-(2,5-dichloropyrimidin-4-yl)-l-(phenylsulfonyl)-1H-indole (0.590g, 1.46mmol), 3,3-dimethylaminopropyldiamine (149mg, 1.46mmol) in EtOH/DMF (4: 1, lOmL) was heated at 130¡ãC (mW) for 20min. The mixture was diluted with EtOAc (30mL), washed with sat. NaHC03 (5mL), brine (5mL) dried (MgS04), filtered and concentrated under reduced pressure to afford the title compound (600mg, 1.28mmol, 87percent) as a white solid which was used in the next step without any further purification.

7328-91-8, The synthetic route of 7328-91-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SYROS PHARMACEUTICALS, INC.; PARAZA PHARMA, INC.; CIBLAT, Stephane; DEROY, Patrick; LEBLANC, Melissa; MARINEAU, Jason, J.; MOORE, Joel; ROY, Stephanie; SIDDIQUI, M., Arshad; SPROTT, Kevin; WINTER, Dana, K.; KABRO, Anzheliika; LEGER, Serge; MILLER, Tom; SCHMIDT, Darby; BRADLEY, Michael; WO2015/58163; (2015); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

153-94-6, H-D-Trp-OH is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

C1. D-Tryptophan methyl ester; The title compound can be obtained by methylesterification of D-tryptophan in methanol with the aid of thionylchloride according to standard procedures., 153-94-6

153-94-6 H-D-Trp-OH 9060, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; ALTANA PHARMA AG; WO2006/79645; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI